BRIEF published on 02/25/2026 at 22:20, 8 months 17 days ago NANOBIOTIX Presents at Key Conferences in March Biotechnology Investor Conferences Cancer Treatments NANOBIOTIX Clinical Advances
PRESS RELEASE published on 02/25/2026 at 22:15, 8 months 17 days ago NANOBIOTIX participera à plusieurs conférences investisseurs en mars Nanobiotix participera à plusieurs conférences investisseurs en mars. Détails sur les événements et les participants. La société présentera ses approches novatrices en biotechnologie Biotechnologie Cancer Conférences Investisseurs NANOBIOTIX Approches Therapeutiques
BRIEF published on 02/17/2026 at 22:20, 8 months 25 days ago Nanobiotix annonce une mise à jour de ses droits de vote et de son capital social Euronext Paris Capital Social Droit De Vote Divulgation Financière NANOBIOTIX
BRIEF published on 02/17/2026 at 22:20, 8 months 25 days ago Nanobiotix Announces Updated Voting Rights and Share Capital Euronext Paris Voting Rights Shares Capital Financial Disclosure NANOBIOTIX
PRESS RELEASE published on 02/17/2026 at 22:15, 8 months 25 days ago Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Nanobiotix publie son information mensuelle sur les droits de vote et actions. La société développe des traitements innovants en biotechnologie Droits De Vote Biotechnologie Actions Traitements NANOBIOTIX
PRESS RELEASE published on 02/17/2026 at 22:15, 8 months 25 days ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital. The biotech company is listed on Euronext Paris and Nasdaq, focusing on disruptive therapies Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 02/02/2026 at 09:44, 9 months 12 days ago Goldman Sachs réduit sa participation dans Nanobiotix Euronext Paris Franchissement De Seuil Goldman Sachs Cession D'actions NANOBIOTIX
BRIEF published on 02/02/2026 at 09:44, 9 months 12 days ago Goldman Sachs reduces its stake in Nanobiotix Euronext Paris Goldman Sachs Threshold Crossing Transfer Of Shares NANOBIOTIX
PRESS RELEASE published on 02/02/2026 at 09:39, 9 months 12 days ago Franchissement de seuils Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. pour Nanobiotix Actions AMF Franchissement De Seuils Goldman Sachs NANOBIOTIX
BRIEF published on 01/26/2026 at 09:56, 9 months 19 days ago Goldman Sachs crosses thresholds in Nanobiotix Voting Rights Goldman Sachs Crossing Thresholds NANOBIOTIX Off-market Acquisition
Published on 11/14/2026 at 12:56, 11 hours 50 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 23 hours 16 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 1 hour ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 2 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 5 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 5 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 1 day 13 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 1 day 13 hours ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 1 day 16 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 1 hour ago Belgrano continues the implementation of its public share buyback offer (OPRA)
